KeyBanc analyst Matthew Mishan maintained a Buy rating on Hill-Rom (NYSE: HRC) today and set a price target of $115. The company’s shares closed yesterday at $91.38, close to its 52-week high of $94.63.
Mishan has an average return of 26.0% when recommending Hill-Rom.
According to TipRanks.com, Mishan is ranked #507 out of 4843 analysts.
Currently, the analyst consensus on Hill-Rom is a Strong Buy with an average price target of $107.33.
See today’s analyst top recommended stocks >>
Based on Hill-Rom’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $28.5 million. In comparison, last year the company had a net profit of $6 million.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Hill-Rom Holdings, Inc. is a medical technology company, which focuses on patient care solutions that improve clinical and economic outcomes. It operates through three segments: Patient Support System, Front Line Care, and Surgical Solutions.
